Navigation Links
ResMed Inc. Announces Financial Results for the Quarter Ended September 30, 2011
Date:10/24/2011

as a result of our recent acquisitions of BiancaMed Ltd. and Grundler GmbH.  The ongoing integration of these units is going well. Stock-based compensation costs incurred during the quarter ended September 30, 2011 of $7.2 million ($5.3 million, net of tax) consisted of expenses associated with stock options, restricted stock units, and the employee stock purchase plan.

Inventory, at $188.0 million, decreased by $12.8 million compared to June 30, 2011. Accounts receivable days sales outstanding, at 71 days, increased by 2 days compared to June 30, 2011.

Peter C. Farrell Ph.D, chairman and chief executive officer, commented, "Revenue in Americas increased by 9% to $169.3 million over the prior year's quarter. Revenue outside Americas increased by 15% to $145.5 million over the prior year's quarter, or a 7% increase on a constant currency basis.  Worldwide, our growth in flow generators was mainly driven by sales of the S9 AutoSet™ and VPAP Adapt SV™.  Patient interface sales continue to perform strongly in all regions. Operating profit for the September quarter was $60.9 million and cash flow from operations was a record $89.5 million, demonstrating excellent operating performance.  During the quarter, we also repurchased 4.4 million shares, at a cost of $124.7 million, as part of our ongoing capital management program.

"Awareness of sleep-disordered breathing and its impact on other disease states continues to grow.  Just last week, at the Congress of the World Sleep Federation, in Kyoto, Japan, the connection between sleep-disordered breathing and both heart failure and type 2 diabetes mellitus was highlighted, with particular emphasis  on the need to address sleep-disordered breathing diagnosis and treatment for patients with type 2 diabetes.  In fact, both Japanese cardiologists and endocrinologists are initiating their own sleep studies to simplify the diagnostic procedures for sleep
'/>"/>

SOURCE ResMed Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ResMed Acquires Laboratoires Narval
2. ResMed Inc Announces Record Financial Results for the Quarter and Six Months Ended December 31, 2009
3. ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2009
4. ResMed Inc. to Present at Upcoming Conferences
5. ResMed Announces Deferred Conversions in Connection With Stock Split
6. ResMed Inc. Announces Completion of Two-for-One Stock Split
7. Study Shows ResMeds New CPAP Device Increases Patient Compliance
8. ResMed Announces Conference Call and Webcast to Discuss First Quarter 2011 Results
9. ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2010
10. ResMed Announces Conference Call and Webcast to Discuss Second Quarter 2011 Results
11. ResMed Inc. Announces Record Financial Results for the Quarter Ended and Six Months Ended December 31, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, ... OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE ... JURISDICTION AbbVie (NYSE: ABBV ) today announced financial ... "This was another very strong quarter for AbbVie, ... original guidance and announced plans to merge with Shire, a ...
(Date:7/24/2014)... OVERLAND PARK, Kan. , July 24, 2014 ... licensing of two compounds that will be added ... agreement with Australian-based CIMTECH Pty Ltd, a biotechnology ... and PAR 122 have shown promise in bone ... a license to develop the compounds for the ...
(Date:7/24/2014)... , and MARSEILLE, France , July ... Exclusive global license from University of Tokyo enables development ... (NGS) gene panels, for blood cancers  Mutations ... indicate favorable prognosis for patients with bone marrow disorders ... for developing companion diagnostics to guide treatment with new ...
Breaking Medicine Technology:AbbVie Reports Second-Quarter 2014 Financial Results 2AbbVie Reports Second-Quarter 2014 Financial Results 3AbbVie Reports Second-Quarter 2014 Financial Results 4AbbVie Reports Second-Quarter 2014 Financial Results 5AbbVie Reports Second-Quarter 2014 Financial Results 6AbbVie Reports Second-Quarter 2014 Financial Results 7AbbVie Reports Second-Quarter 2014 Financial Results 8AbbVie Reports Second-Quarter 2014 Financial Results 9AbbVie Reports Second-Quarter 2014 Financial Results 10AbbVie Reports Second-Quarter 2014 Financial Results 11AbbVie Reports Second-Quarter 2014 Financial Results 12AbbVie Reports Second-Quarter 2014 Financial Results 13AbbVie Reports Second-Quarter 2014 Financial Results 14AbbVie Reports Second-Quarter 2014 Financial Results 15AbbVie Reports Second-Quarter 2014 Financial Results 16AbbVie Reports Second-Quarter 2014 Financial Results 17AbbVie Reports Second-Quarter 2014 Financial Results 18AbbVie Reports Second-Quarter 2014 Financial Results 19AbbVie Reports Second-Quarter 2014 Financial Results 20AbbVie Reports Second-Quarter 2014 Financial Results 21AbbVie Reports Second-Quarter 2014 Financial Results 22AbbVie Reports Second-Quarter 2014 Financial Results 23AbbVie Reports Second-Quarter 2014 Financial Results 24AbbVie Reports Second-Quarter 2014 Financial Results 25AbbVie Reports Second-Quarter 2014 Financial Results 26AbbVie Reports Second-Quarter 2014 Financial Results 27AbbVie Reports Second-Quarter 2014 Financial Results 28AbbVie Reports Second-Quarter 2014 Financial Results 29AbbVie Reports Second-Quarter 2014 Financial Results 30AbbVie Reports Second-Quarter 2014 Financial Results 31AbbVie Reports Second-Quarter 2014 Financial Results 32AbbVie Reports Second-Quarter 2014 Financial Results 33AbbVie Reports Second-Quarter 2014 Financial Results 34AbbVie Reports Second-Quarter 2014 Financial Results 35AbbVie Reports Second-Quarter 2014 Financial Results 36
... 9 Pharmacyclics, Inc.,(Nasdaq: PCYC ) today ... orally available, selective inhibitor of Bruton,s tyrosine,kinase, or ... model,for rheumatoid arthritis (RA). The data were presented ... being held this,week in Boston, MA., Researchers ...
... shows, investigational regimen resulted in 82 percent overall survival and 78 ... ... is presently being conducted in this ... patient population, LUGANO, Switzerland, June 9 In an ...
Cached Medicine Technology:Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma 2Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma 3Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma 4Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma 2Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma 3Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma 4
(Date:7/25/2014)... (HealthDay News) -- The human brain can preserve oxygen ... new study finds. Although dehydration significantly reduces ... found that the brain compensates by increasing the amount ... research has helped us understand a lot more about ... extreme conditions," study first author Steven Trangmar, a researcher ...
(Date:7/25/2014)... Ticket Down is a reliable source for ... at California Memorial Stadium. With the post-World Cup emotions ... organizers of the 2014 Guinness International Champions Cup have brought ... With teams representing La Liga, English Premier League, Serie A, ... best football players from around the world to 12 American ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 This ... current state of the Galactooligosaccharides (GOS) industry ... basic overview of the industry, including definitions, applications ... Chinese domestic market analysis are provided with a ... of the market. A comparison between the international ...
(Date:7/25/2014)... News) -- Babies seem to learn even before they,re ... women are 34 weeks pregnant, their unborn babies can ... a familiar nursery rhyme, the researchers report. "The ... in the developing fetus," Charlene Krueger, nursing researcher and ... Nursing, said in a university news release. "This research ...
(Date:7/25/2014)... Newyorktermlifeinsurance.org has released a new blog post ... policies. , The newly released blog post aims ... exam life insurance plans and traditional policies. The article ... to provide a simple guide for purchasing life coverage. ... be purchased online. Although traditional plans do not have ...
Breaking Medicine News(10 mins):Health News:Human Brain Has Coping Mechanism for Dehydration 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 3Health News:GOS Market (Galacto-oligosaccharides) Development in Global & China Regions Now Available at DeepResearchReports.com 2Health News:GOS Market (Galacto-oligosaccharides) Development in Global & China Regions Now Available at DeepResearchReports.com 3Health News:Rhymes Reveal Evidence of Learning in the Womb 2Health News:No Medical Exam Life Insurance and Traditional Plans - Newyorktermlifeinsurance.org Provides Quotes for All Types of Life Insurance 2
... Work and economy related stress is taking its toll on ... by American Laser Centers, the largest provider of non-invasive aesthetic services ... part in the survey (47 percent) currently feel some stress, while ... , The physical toll of their stress is also ...
... , SPRINGFIELD, Ohio, Aug. 14 AdCare Health Systems, ... term care, home care and management company, today reported financial results ... Revenues for the quarter ended June 30, 2009 were $6,613,127 as ... of $596,591. The increase was mostly due to improved occupancy in ...
... avoid becoming overweight, researchers say , FRIDAY, Aug. 14 ... obesity epidemic by forbidding their kids to eat certain foods ... may actually be making the situation worse, researchers say. ... food choices that will allow them to maintain a healthy ...
... , , SALT LAKE CITY, ... and respected brands in the nutritional supplement industry, having provided consumers ... years, is excited to announce the seven lucky winners of the ... Each grand prize winner won a 10-day vacation for two ...
... , , RICHMOND, ... TSPT ), a specialty pharmaceutical company focused on the development ... in neuroscience, today announced financial results for the three and ... Glenn A. Oclassen, President and Chief Executive Officer commented, ...
... , , , ... OXBO) today announced that the company has received approval to begin ... of Oxycyte(R) in traumatic brain injury (TBI). Oxycyte is the Company,s ... approval from Swissmedic means that we can begin enrolling patients," said ...
Cached Medicine News:Health News:AdCare Health Systems, Inc. Continues To Be Profitable; Reports 2009 Second Quarter Earning Results 2Health News:AdCare Health Systems, Inc. Continues To Be Profitable; Reports 2009 Second Quarter Earning Results 3Health News:AdCare Health Systems, Inc. Continues To Be Profitable; Reports 2009 Second Quarter Earning Results 4Health News:AdCare Health Systems, Inc. Continues To Be Profitable; Reports 2009 Second Quarter Earning Results 5Health News:AdCare Health Systems, Inc. Continues To Be Profitable; Reports 2009 Second Quarter Earning Results 6Health News:AdCare Health Systems, Inc. Continues To Be Profitable; Reports 2009 Second Quarter Earning Results 7Health News:AdCare Health Systems, Inc. Continues To Be Profitable; Reports 2009 Second Quarter Earning Results 8Health News:AdCare Health Systems, Inc. Continues To Be Profitable; Reports 2009 Second Quarter Earning Results 9Health News:AdCare Health Systems, Inc. Continues To Be Profitable; Reports 2009 Second Quarter Earning Results 10Health News:Restrictive Diet for Kids May Backfire 2Health News:Schiff Awards Seven Lucky Winners the 'Trip of a Lifetime' 2Health News:Schiff Awards Seven Lucky Winners the 'Trip of a Lifetime' 3Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 2Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 3Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 4Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 5Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 6Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 7Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 8Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 9Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 10Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 11Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 12Health News:Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 13Health News:Oxygen Biotherapeutics, Inc. to Begin Oxycyte(R) Phase II Clinical Trials in Switzerland 2Health News:Oxygen Biotherapeutics, Inc. to Begin Oxycyte(R) Phase II Clinical Trials in Switzerland 3
The precise, fully reusable R-100 Pullback Device is an invaluable tool during plaque volumetric analysis....
... you perform exams from cardiac to angio. ... no compromises. An ideal 31 centimeters square, ... of cardiovascular and interventional imaging. With a ... variety of vascular and interventional procedures. The ...
... The RX daytona is a fully ... field in bench top analysers offering many ... standing systems. With reusable glass cuvettes, on ... and reagents, the random access analyser can ...
Inquire...
Medicine Products: